Your Sorted CME/CE Activities

Emerging Therapy Approaches for High-Risk Myelodysplastic Syndromes (MDS) - Conversation 2 of 2
Certified AMA/ANCC/ACPE Activity

Until recently, there has been a lack of treatment options for high-risk MDS. An increased understanding of the genetics and signaling pathways has led to the development of several novel agents and combinations for the treatment of high-risk MDS.

In this activity, Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji will deliberate on the most promising emerging therapies and their potential in improving outcomes for patients with high-risk MDS.
Review this activity and claim AMA or ANCC credit/contact hour(s) after completion of the post-test / evaluation.








 Courtney DiNardo, MD, MSCE Courtney DiNardo, MD, MSCE
Associate Professor
UT MD Anderson Cancer Center
 Rami Komrokji, MD Rami Komrokji, MD
Section Head - Leukemia & MDS, Vice Chair Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
Morsani College of Medicine, University of South Florida
Gail Roboz, MD Gail Roboz, MD
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Cornell Medicine
The New York Presbyterian Hospital

20
Supported by independent educational grants from Genentech, Novartis, Taiho and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Launch Date: December 6, 2021
Release Date: November 30, 2021
Expiration Date: September 30, 2022

September 30, 2022
Mini Module
7231
ConversationsInMDS_WebBanner(1150).gif
Hem-Onc